{"page_content": "ESG R eport 2021AGIOS PHARMACEUTICALS\nWe are the pioneering leaders in pyruvate kinase R (PKR) activation. Agios intends to move forward with a singular focus on accelerating and \nexpanding our genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates \nbased on our expertise in cellular metabolism and PK activation.\n7 YEARS\n1st GLOBAL PK \nDEFICIENCY REGISTRY1st INTERNATIONAL PK \nDEFICIENCY ADVOCACY \nCOUNCIL1st HEMOLYTIC ANEMIA \nADVOCACY COALITION \nBUILDING1st POSITIVE PHASE \n3 READOUT IN PK \nDEFICIENCYPatients Treated Diseases with  \nProof-of-Concept \nAchievedClinical Trials Journal Articles  \nPublishedMedical/Scientific  \nCollaborations~190 3 17 15 17STUDYING PKR ACTIVATION IN THE CLINIC\nPLUS A LOT OF FIRSTS\n6", "metadata": {"source": "NASDAQ_AGIO_2020.pdf", "page": 5, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}